 |
GENERIC NAME:
Enrofloxacin Tabletst
MAIN COMPONENT:
Enrofloxacin
DESCRIPTION:
The product is an off-white tablet.
PHARMACOLOGICAL EFFECTS:
Pharmacodynamics Enrofloxacin is a broad-spectrum antimicrobial drug of the fluoroquinolone class for animals. It works well against Escherichia coli, Salmonella, Klebsiella, Brucella, Pasteurella, Actinobacillus pleuropneumoniae, Dengue bacillus, Aspergillus, Serratia marcescens, Corynebacterium pyogenes, Bordetella bronchiseptica (Bb), Staphylococcus aureus, mycoplasma, chlamydia, etc. It has weak antibacterial activity against Pseudomonas aeruginosa and Streptococcus, and slight antibacterial activity against anaerobic bacteria. It possesses a significant postantibiotic effect (PAE) against susceptible bacteria. The mechanism of its antibacterial action is that it acts on bacterial DNA gyrase to interfere with the replication, transcription and recombinational repair of bacterial DNA, so that bacteria cannot grow/reproduce normally and die.
Pharmacokinetics The product is well absorbed in most animals when administered orally. Its bioavailability in dogs is about 80%, with 50% of the peak concentration reached at 15min after oral administration and a peak reached within 1h. It is widely distributed in the animal's body and enters tissues and body fluids well. Its concentration in almost all tissues except the cerebrospinal fluid is higher than that in plasma. Liver metabolism is mainly the removal of 7-piperazine ring ethyl to generate ciprofloxacin, followed by oxidation and glucuronic acid binding. It is excreted mainly through the kidneys (via tubular secretion and glomerular filtration), as 15%-50% is excreted unchanged in urine. Its half-life is 3.7-5.8h in dogs and 6h in cats after oral administration.
DRUG INTERACTIONS:
The product acts synergistically with aminoglycosides or broad-spectrum penicillin.
The product can chelate with heavy metal ions such as Ca2+, Mg2+, Fe3+ and Al3+ and then affect its absorption.
When combined with theophylline and caffeine, it can reduce the plasma protein binding rate, abnormally increase the concentrations of theophylline and caffeine in blood, and even cause symptoms of theophylline poisoning.
The product can inhibit hepatic microsomal mixed function oxidases to reduce the clearance of drugs mainly metabolized in the liver, and increase their blood concentrations.
DOSAGE AND ADMINISTRATION:
Calculated based on pimobendan. Oral dose for dogs: 0.25 mg/kg body weight twice daily.
INDICATIONS AND USAGE:
It is a fluoroquinolone antibacterial drug. It is used for bacterial diseases and mycoplasma infection in animals.DOSAGE AND ADMINISTRATION:
Calculated based on enrofloxacin. Oral dose for dogs and cats: 2.5-5 mg/kg body weight twice daily for 3-5 days. Or follow medical advice.
ADVERSE REACTIONS:
It can cause articular cartilage degeneration in young animals, affect bone development and cause claudication & pain.
Adverse reactions in the digestive system include vomiting, inappetence and diarrhea.
Skin reactions include erythema, pruritus, urticaria and photosensitivity.
Allergic reactions, ataxia and epileptic seizures occasionally occur in dogs and cats.
PRECAUTIONS:
It has a potential excitatory effect on the central system to induce epileptic seizures, so it should be used with caution in dogs with epilepsy.
It should be used with caution in animals with poor kidney function, because it can cause occasional crystalluria.
Intramuscular injection can cause transient irritation.
The product is contraindicated in cats under 8 weeks of age, small dogs aged ≤12 months and large dogs aged ≤18 months.
There tends to be an increase in strains resistant to the product, so it should not be used at subtherapeutic doses for long time.
Specially developed for pet infectious diseases, it has a powerful bactericidal effect by directly destroying bacterial cell DNA.
After oral administration, it can reach 50% of the peak concentration within 15 minutes and reach the maximum blood drug concentration within 1 hour.
Maintain extremely high concentrations in inflammatory tissues.
| WITHDRAWAL PERIOD | Not required for its establishment |
| STRENGTH | 25 mg |
| PACKAGING | 7 tablets/plate × 4 plates/box. |
| SHELF LIFE | 2 years |
GENERIC NAME:
Enrofloxacin Tabletst
MAIN COMPONENT:
Enrofloxacin
DESCRIPTION:
The product is an off-white tablet.
PHARMACOLOGICAL EFFECTS:
Pharmacodynamics Enrofloxacin is a broad-spectrum antimicrobial drug of the fluoroquinolone class for animals. It works well against Escherichia coli, Salmonella, Klebsiella, Brucella, Pasteurella, Actinobacillus pleuropneumoniae, Dengue bacillus, Aspergillus, Serratia marcescens, Corynebacterium pyogenes, Bordetella bronchiseptica (Bb), Staphylococcus aureus, mycoplasma, chlamydia, etc. It has weak antibacterial activity against Pseudomonas aeruginosa and Streptococcus, and slight antibacterial activity against anaerobic bacteria. It possesses a significant postantibiotic effect (PAE) against susceptible bacteria. The mechanism of its antibacterial action is that it acts on bacterial DNA gyrase to interfere with the replication, transcription and recombinational repair of bacterial DNA, so that bacteria cannot grow/reproduce normally and die.
Pharmacokinetics The product is well absorbed in most animals when administered orally. Its bioavailability in dogs is about 80%, with 50% of the peak concentration reached at 15min after oral administration and a peak reached within 1h. It is widely distributed in the animal's body and enters tissues and body fluids well. Its concentration in almost all tissues except the cerebrospinal fluid is higher than that in plasma. Liver metabolism is mainly the removal of 7-piperazine ring ethyl to generate ciprofloxacin, followed by oxidation and glucuronic acid binding. It is excreted mainly through the kidneys (via tubular secretion and glomerular filtration), as 15%-50% is excreted unchanged in urine. Its half-life is 3.7-5.8h in dogs and 6h in cats after oral administration.
DRUG INTERACTIONS:
The product acts synergistically with aminoglycosides or broad-spectrum penicillin.
The product can chelate with heavy metal ions such as Ca2+, Mg2+, Fe3+ and Al3+ and then affect its absorption.
When combined with theophylline and caffeine, it can reduce the plasma protein binding rate, abnormally increase the concentrations of theophylline and caffeine in blood, and even cause symptoms of theophylline poisoning.
The product can inhibit hepatic microsomal mixed function oxidases to reduce the clearance of drugs mainly metabolized in the liver, and increase their blood concentrations.
DOSAGE AND ADMINISTRATION:
Calculated based on pimobendan. Oral dose for dogs: 0.25 mg/kg body weight twice daily.
INDICATIONS AND USAGE:
It is a fluoroquinolone antibacterial drug. It is used for bacterial diseases and mycoplasma infection in animals.DOSAGE AND ADMINISTRATION:
Calculated based on enrofloxacin. Oral dose for dogs and cats: 2.5-5 mg/kg body weight twice daily for 3-5 days. Or follow medical advice.
ADVERSE REACTIONS:
It can cause articular cartilage degeneration in young animals, affect bone development and cause claudication & pain.
Adverse reactions in the digestive system include vomiting, inappetence and diarrhea.
Skin reactions include erythema, pruritus, urticaria and photosensitivity.
Allergic reactions, ataxia and epileptic seizures occasionally occur in dogs and cats.
PRECAUTIONS:
It has a potential excitatory effect on the central system to induce epileptic seizures, so it should be used with caution in dogs with epilepsy.
It should be used with caution in animals with poor kidney function, because it can cause occasional crystalluria.
Intramuscular injection can cause transient irritation.
The product is contraindicated in cats under 8 weeks of age, small dogs aged ≤12 months and large dogs aged ≤18 months.
There tends to be an increase in strains resistant to the product, so it should not be used at subtherapeutic doses for long time.
Specially developed for pet infectious diseases, it has a powerful bactericidal effect by directly destroying bacterial cell DNA.
After oral administration, it can reach 50% of the peak concentration within 15 minutes and reach the maximum blood drug concentration within 1 hour.
Maintain extremely high concentrations in inflammatory tissues.
| WITHDRAWAL PERIOD | Not required for its establishment |
| STRENGTH | 25 mg |
| PACKAGING | 7 tablets/plate × 4 plates/box. |
| SHELF LIFE | 2 years |
